Filing Flows › Health Care › Lensar (LNSR)
Lensar (LNSR) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Lensar (LNSR) Q2 2026 earnings results →
Q2 2026 Revenue up 18% year over year to $16.5M · 21¢ of every $1 of revenue kept as net profit · operating margin 12.9%
Lensar made $16.5M in Q2 2026 (+18% Y/Y): Product $13.0M, Other revenues $1.8M, Service $1.7M. Operating margin 12.9%, net earnings $3.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $16.5M in Q2 2026, up 18% year over year and up 23% from the previous quarter. Product was the largest line at 79% of revenue. Product added $2.1M year over year (up 20%), 83% of the total change.
Operating profit was $2.1M, a 12.9% margin (up 58.1 points year over year). Total costs fell 29% while revenue rose 18%. Net earnings were $3.5M. The effective tax rate was 0.0%. Non-operating items added $1.4M, 40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$127K. Non-cash charges added back $1.1M of depreciation and amortization and $347K of share-based compensation. Working capital and other items used $5.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $16.5M | +18% | 12.9% | $3.5M | −$127K |
| Q1 2026 | 10-Q | May 8, 2026 | $13.4M | -5% | 16.7% | $36.3M | −$4.3M |
| Q4 2025 | 10-K | Mar 31, 2026 | $16.0M | -4% | -30.7% | −$1.5M | $618K |
| Q3 2025 | 10-Q | Nov 6, 2025 | $14.3M | +6% | -52.9% | −$3.7M | −$3.5M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $13.9M | +10% | -45.1% | −$1.8M | −$5.0M |
| Q1 2025 | 10-Q | May 8, 2025 | $14.2M | +34% | -40.9% | −$27.3M | −$6.9M |
| Q4 2024 | 10-K | Feb 27, 2025 | $16.7M | +38% | -7.7% | −$18.7M | $3.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lensar
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System ® as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, designed to guide surgeons to achieve better outcomes.
In its own words, from its 8-K, filed Aug 13, 2026.
Lensar against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +18% against the peers' median +5%. Operating margin: 12.9% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LNSR Lensar | Q2 2026 | $16.5M | +18% | 12.9% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Lensar 10-Q on SEC EDGAR · CIK 1320350 · Surgical & Medical Instruments & Apparatus
13F: who owns LNSR and who is buying
More on LNSR
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results